Cover |
Oct. 04, 2024 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | On October 7, 2024, Sigyn Therapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) reporting that the holders of $474,793 of Original Issue Discount Senior Convertible Debentures elected to convert their debentures at an average contractual exercise price of $4.00 per share in exchange for the issuance of 118,700 shares of the Company’s Common Stock to the holders. In the Original Form 8-K the Company stated the issuance of the Common Stock was “exempt from registration pursuant to Section 4(a)(2) of the Securities Act promulgated thereunder as the Sellers are controlled by one of executive officers who is an accredited investor and familiar with the Company’s operations.” The statement that the Sellers “are controlled by one of executive officers” was in error. None of the Sellers are controlled by any of the Company’s executive officers. The correct, amended disclosure is contained in Item 3.02, below. |
| Document Period End Date | Oct. 04, 2024 |
| Entity File Number | 000-55575 |
| Entity Registrant Name | SIGYN THERAPEUTICS, INC. |
| Entity Central Index Key | 0001642159 |
| Entity Tax Identification Number | 84-4210559 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 2468 Historic Decatur Road |
| Entity Address, Address Line Two | Suite 140 |
| Entity Address, City or Town | San Diego |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 92106 |
| City Area Code | 619 |
| Local Phone Number | 353.0800 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Emerging Growth Company | false |